PURPOSE: Few studies have evaluated the use of intensity-modulated radiotherapy (IMRT) for squamous cell carcinoma (SCC) of the oral cavity (OC). We report clinical outcomes and failure patterns for these patients. METHODS AND MATERIALS: Between October 2002 and June 2009, 37 patients with newly diagnosed SCC of the OC underwent postoperative (30) or definitive (7) IMRT. Twenty-five patients (66%) received systemic therapy. The median follow-up was 38 months (range, 10-87 months). The median interval from surgery to RT was 5.9 weeks (range, 2.1-10.7 weeks). RESULTS: Thirteen patients experienced local-regional failure at a median of 8.1 months (range, 2.4-31.9 months), and 2 additional patients experienced local recurrence between surgery and RT. Seven local failures occurred in-field (one with simultaneous nodal and distant disease) and two at the margin. Four regional failures occurred, two in-field and two out-of-field, one with synchronous metastases. Six patients experienced distant failure. The 3-year actuarial estimates of local control, local-regional control, freedom from distant metastasis, and overall survival were 67%, 53%, 81%, and 60% among postoperative patients, respectively, and 60%, 60%, 71%, and 57% among definitive patients. Four patients developed Grade ≥ 2 chronic toxicity. Increased surgery to RT interval predicted for decreased LRC (p = 0.04). CONCLUSIONS: Local-regional control for SCC of the OC treated with IMRT with or without surgery remains unsatisfactory. Definitive and postoperative IMRT have favorable toxicity profiles. A surgery-to-RT interval of < 6 weeks improves local-regional control. The predominant failure pattern was local, suggesting that both improvements in target delineation and radiosensitization and/or dose escalation are needed.
PURPOSE: Few studies have evaluated the use of intensity-modulated radiotherapy (IMRT) for squamous cell carcinoma (SCC) of the oral cavity (OC). We report clinical outcomes and failure patterns for these patients. METHODS AND MATERIALS: Between October 2002 and June 2009, 37 patients with newly diagnosed SCC of the OC underwent postoperative (30) or definitive (7) IMRT. Twenty-five patients (66%) received systemic therapy. The median follow-up was 38 months (range, 10-87 months). The median interval from surgery to RT was 5.9 weeks (range, 2.1-10.7 weeks). RESULTS: Thirteen patients experienced local-regional failure at a median of 8.1 months (range, 2.4-31.9 months), and 2 additional patients experienced local recurrence between surgery and RT. Seven local failures occurred in-field (one with simultaneous nodal and distant disease) and two at the margin. Four regional failures occurred, two in-field and two out-of-field, one with synchronous metastases. Six patients experienced distant failure. The 3-year actuarial estimates of local control, local-regional control, freedom from distant metastasis, and overall survival were 67%, 53%, 81%, and 60% among postoperative patients, respectively, and 60%, 60%, 71%, and 57% among definitive patients. Four patients developed Grade ≥ 2 chronic toxicity. Increased surgery to RT interval predicted for decreased LRC (p = 0.04). CONCLUSIONS: Local-regional control for SCC of the OC treated with IMRT with or without surgery remains unsatisfactory. Definitive and postoperative IMRT have favorable toxicity profiles. A surgery-to-RT interval of < 6 weeks improves local-regional control. The predominant failure pattern was local, suggesting that both improvements in target delineation and radiosensitization and/or dose escalation are needed.
Authors: Michael T Spiotto; Gina Jefferson; Barry Wenig; Michael Markiewicz; Ralph R Weichselbaum; Matthew Koshy Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-07-01 Impact factor: 6.223
Authors: Dennis M Sopka; Tianyu Li; Miriam N Lango; Ranee Mehra; Jeffrey Chang-Jen Liu; Barbara Burtness; Douglas B Flieder; John A Ridge; Thomas J Galloway Journal: Oral Oncol Date: 2013-09-17 Impact factor: 5.337
Authors: Omar K Jilani; Prabhsimranjot Singh; A Gabriella Wernicke; David I Kutler; William Kuhel; Paul Christos; Dattatreyudu Nori; Albert Sabbas; Ks Clifford Chao; Bhupesh Parashar Journal: J Geriatr Oncol Date: 2012-10 Impact factor: 3.599
Authors: Sean R Quinlan-Davidson; Abdallah S R Mohamed; Jeffrey N Myers; Gary B Gunn; Faye M Johnson; Heath Skinner; Beth M Beadle; Ann M Gillenwater; Jack Phan; Steven J Frank; William N William; Andrew J Wong; Stephen Y Lai; Clifton D Fuller; William H Morrison; David I Rosenthal; Adam S Garden Journal: Oral Oncol Date: 2017-07-16 Impact factor: 5.337
Authors: Alexander Gröbe; Lena Rybak; Gerhard Schön; Ralf Smeets; Silke Tribius; Philippe Schafhausen; Till S Clauditz; Henning Hanken; Max Heiland Journal: J Cancer Res Clin Oncol Date: 2015-10-27 Impact factor: 4.553
Authors: Gabriela Studer; Michelle Brown; Marius Bredell; Klaus W Graetz; Gerhard Huber; Claudia Linsenmeier; Yousef Najafi; Oliver Riesterer; Tamara Rordorf; Stephan Schmid; Christoph Glanzmann Journal: Radiat Oncol Date: 2012-06-11 Impact factor: 3.481
Authors: Krupal B Patel; Daniel Martin; Songzhu Zhao; Bhavna Kumar; Ricardo Carrau; Enver Ozer; Amit Agrawal; Stephen Kang; James W Rocco; David Schuller; Theodoros Teknos; Guy Brock; Matthew Old Journal: Head Neck Date: 2020-09-30 Impact factor: 3.147